<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427243</url>
  </required_header>
  <id_info>
    <org_study_id>GP29172</org_study_id>
    <nct_id>NCT02427243</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose</brief_title>
  <official_title>A Phase 1, Single-Dose, Randomized, Open-Label, Parallel Group Study to Assess the Relative Bioavailability and Tolerability of Two Formulations of Crenezumab in Healthy Subjects Following Subcutaneous Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      To assess the relative bioavailability and tolerability of two different formulations of
      crenezumab in approximately 60 healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of crenezumab (Cmax, tmax, AUC0-last, AUC(0-infinity), Vz/F, CL/F, Apparent terminal elimination rate constant, and t1/2)</measure>
    <time_frame>Day 1 through Day 85 or early termination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Consent through Day 85 or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies (ATAs) to crenezumab</measure>
    <time_frame>From Day 1 (Predose) through Day 85 or early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Crenezumab Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose given as two subcutaneous injections on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crenezumab Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose given as two subcutaneous injections on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenezumab</intervention_name>
    <arm_group_label>Crenezumab Formulation 3</arm_group_label>
    <other_name>RO5490245 or MABT5102A (formerly)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenezumab</intervention_name>
    <arm_group_label>Crenezumab Formulation 2</arm_group_label>
    <other_name>RO5490245 or MABT5102A (formerly)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female 18 to 65 years of age at Screening, inclusive

          -  Body mass index (BMI) 18.5 to 32 kg/m^2, inclusive

          -  Body weight 50 to 100 kg, inclusive

          -  Females must be of non-childbearing potential

          -  Males of reproductive potential must agree to remain abstinent or must be using highly
             effective contraception and must avoid sperm donation, from Screening until at least 8
             weeks after the last study drug administration or until study completion, whichever is
             later

        Exclusion Criteria:

          -  Significant medical history, psychiatric disorder, or acute infection at Screening (as
             determined by Investigator)

          -  History of alcoholism or drug addiction within 6 months prior to CRU Check-in

          -  Use of tobacco or nicotine-containing products from 6 months prior to CRU Check-in and
             during the study

          -  Participation in any other investigational study drug trial in which receipt of an
             investigational study drug occurred wtihin 30 days or 5 half-lives, whichever is
             longer, prior to CRU Check-in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

